Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
1.39
0.00 (0.00%)
Mar 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.33 - 3.58
Open     -
Vol / Avg. 0.00/3.41M
Mkt cap 213.82M
P/E     -
Div/yield     -
EPS -0.31
Shares 153.83M
Beta 1.17
Inst. own 15%
May 7, 2015
Q1 2015 Galena Biopharma Inc Earnings Release (Tentative) - 4:00PM EDT - Add to calendar
Apr 14, 2015
Galena Biopharma Inc at Needham Healthcare Conference - 10:40AM EDT - Add to calendar
Mar 24, 2015
Galena Biopharma Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 9, 2015
Galena Biopharma Inc at ROTH Conference
Mar 5, 2015
Q4 2014 Galena Biopharma Inc Earnings Call - Webcast
Mar 5, 2015
Q4 2014 Galena Biopharma Inc Earnings Release
Feb 10, 2015
Galena Biopharma Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 20, 2015
Galena Biopharma Inc at Noble Financial Equity Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -249.01% -392.81%
Operating margin -349.08% -558.56%
EBITD margin - -550.84%
Return on average assets -39.89% -43.46%
Return on average equity -93.97% -170.48%
Employees 57 -
CDP Score - -

Address

SUITE 270, 4640 SW MACADAM AVENUE
PORTLAND, OR 97239
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galena Biopharma, Inc. (Galena) is a biopharmaceutical company. The Company is focused on developing and commercializing oncology therapeutics that address medical needs across a spectrum of cancer care. Galena�s development portfolio ranges from mid- to late-stage clinical assets, including an immunotherapy program led by NeuVax (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company�s commercial drugs include Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film. It also offers peptide immunotherapy product candidate, GALE-301 (Folate Binding Protein), an immunogenic peptide combined with rhGM-CSF that can stimulate cytotoxic T lymphocyte (CTLs) to recognize and destroy Folate Binding Protein (FBP) expressing cancer cells.

Officers and directors

Sanford J. Hillsberg J.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Ryan M. Dunlap Chief Financial Officer, Vice President, Secretary
Age: 44
Bio & Compensation  - Reuters
Joseph Lasaga Vice President - Business Development
Bio & Compensation  - Reuters
Irving M. Einhorn Director
Age: 72
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 64
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven A. Kriegsman Independent Director
Age: 73
Bio & Compensation  - Reuters